8-K
filed March 22, 2023, 7:59 PM ET
ticker ESPR
CIK 0001434868
other material
confidence high
sentiment neutral
materiality 0.75
Esperion raises ~$56.7M in registered direct offering; amends warrants to lower exercise price
Esperion Therapeutics, Inc.
- Gross proceeds of ~$56.7M from sale of 33,170,747 shares (or equivalents) and warrants at $1.675 combined.
- Net proceeds expected ~$51.3M after placement agent fees and expenses.
- Short-term warrants exercisable at $1.55/share for 3.5 years; pre-funded warrants also offered.
- Amended 9,024,212 existing warrants from $9.00 to $1.55 exercise price for $0.125 per amended warrant.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Esperion Therapeutics, Inc. entered into Securities Purchase Agreement with certain purchasers named therein (effective 2023-03-19).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain purchasers named therein
- Effective
- 2023-03-19
Exact text from the filing
On March 19, 2023, Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain purchasers named therein (the “Purchasers”)
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Esperion Therapeutics, Inc. amended Warrant Amendment Agreements valued at approximately $1.13 million (effective 2023-12-07).
- Action
- amendment
- Value
- approximately $1.13 million
- Effective
- 2023-12-07
Exact text from the filing
In connection with the Offering, the Company amended, pursuant to Warrant Amendment Agreements (the “Warrant Amendment Agreements”), certain existing warrants to purchase up to an aggregate of 9,024,212 shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Esperion Therapeutics, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2023-03-16).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
- Effective
- 2023-03-16
Exact text from the filing
Pursuant to a letter agreement, dated March 16, 2023 (the “Engagement Letter”), the Company engaged H.C. Wainwright & Co., LLC as its exclusive placement agent (the “Placement Agent”) in connection with the Offering.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.